This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cost-Effectiveness of Percutaneous Coronary Intervention with Drug-Eluting Stents vs. Bypass Surgery for Patients with 3-Vessel or Left Main Coronary Artery Disease: Final Results from the SYNTAX Trial.
In this study the cost-effectiveness of CABG vs. DES-PCI was analysed from a U.S. Healthcare perspective. Using 5-year cost and quality-of-life data from the SYNTAX trial and lifetime extrapolations, the authors found that CABG was an economically attractive treatment option for most patients with 3-VD or left main CAD disease.